Alexandro W. L. Chu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandro W. L. Chu has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
- Derek K. Chu
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
7 shared publications Daniel G. Rayner
Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada; Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
4 shared publicationsDonna D. Gardner
Allergy & Asthma Network, Fairfax, Virginia, USA
4 shared publicationsKathryn E. Wheeler
Department of Pediatrics, University of Florida, Gainesville, Florida, USA
4 shared publicationsRachel N. Asiniwasis
Division of Dermatology, Department of Medicine, University of Saskatchewan, Regina, Saskatchewan, Canada
4 shared publicationsWinfred T. Frazier
Department of Family Medicine, UPMC St. Margaret, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
4 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
Comparative efficacy and safety of antihistamines, increased antihistamine dosing (updosing), and antihistamine adjuncts for chronic urticaria: Systematic review, dose–response, and network meta-analysis of randomized trials
- 17 October 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
Open AccessComparative efficacy and safety of antihistamines, increased antihistamine dosing (updosing), and antihistamine adjuncts for chronic urticaria: Systematic review, dose–response, and network meta-analysis of randomized trials
- Open Access
Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials
Objective: To systematically synthesise the benefits and harms of add-on oral antihistamines for managing atopic dermatitis (eczema). Design: Systematic review and network meta-analysis of randomised trials. Data sources: Medline, Embase, CENTRAL, the United States Food and Drug Administration, and the European Medicines Agency databases from database inception to 5 May 2025. Study selection: Randomised trials assessing add-on oral H1 antihistamines, H2 blockers, mast cell stabilisers (nedocromil sodium and sodium cromoglycate), or their combinations. Paired reviewers independently screened records, extracted data, and assessed risk of bias using a modified Cochrane Risk of Bias tool version 2. Methods: Random effects bayesian meta-analyses synthesised atopic dermatitis severity (oSCORAD—objective scoring atopic dermatitis, 0-83; minimal important difference 8.2; lower better), itch severity (numerical rating scale, 0-10; minimal important difference 3; lower better), sleep disturbance, atopic dermatitis related quality of life, and harms. The network meta-analysis GRADE (Grading of Recommendations Assessment, Development and Evaluation) and Core GRADE approaches informed certainty of evidence ratings. Results: 47 trials enrolled 6230 children and adults with primarily moderate to severe atopic dermatitis. With moderate certainty, compared with placebo, adding a first generation or second generation H1 antihistamine likely resulted in a small reduction in atopic dermatitis severity (mean difference -1.87, 95% credible interval -3.47 to -0.27) and itch severity (-0.89, -1.41 to -0.37). Although statistically detectable, these effects are well below established minimal important differences (smallest change in an outcome that a patient would identify as important). With low certainty, all studied interventions may not improve sleep disturbance or reduce atopic dermatitis exacerbations. First generation agents probably increase cognitive impairment and may increase treatment discontinuation because of adverse events (risk difference 66 more per 1000, 95% credible interval 0 to 231 more; moderate certainty). Second generation agents differ in their risk of cognitive impairment (range of mean effects 0 more per 1000 for loratadine, 16 more per 1000 for levocetirizine, and 17 more per 1000 for cetirizine). Conclusions: Among patients with atopic dermatitis, adding H1 antihistamines probably results in a clinically unimportant reduction in atopic dermatitis severity and itch severity, and may not reduce sleep disturbance or atopic dermatitis exacerbations. First generation agents increase cognitive impairment and may increase treatment discontinuation because of adverse events. Cognitive impairment risk differs among second generation agents. These findings provide evidence against routine antihistamine use in atopic dermatitis management and will inform updated clinical guidelines. Systematic review registration: PROSPERO NCT42022345643 .
Open AccessAntihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials
Objective: To systematically synthesise the benefits and harms of add-on oral antihistamines for managing atopic dermatitis (eczema). Design: Systematic review and network meta-analysis of randomised trials. Data sources: Medline, Embase, CENTRAL, the United States Food and Drug Administration, and the European Medicines Agency databases from database inception to 5 May 2025. Study selection: Randomised trials assessing add-on oral H1 antihistamines, H2 blockers, mast cell stabilisers (nedocromil sodium and sodium cromoglycate), or their combinations. Paired reviewers independently screened records, extracted data, and assessed risk of bias using a modified Cochrane Risk of Bias tool version 2. Methods: Random effects bayesian meta-analyses synthesised atopic dermatitis severity (oSCORAD—objective scoring atopic dermatitis, 0-83; minimal important difference 8.2; lower better), itch severity (numerical rating scale, 0-10; minimal important difference 3; lower better), sleep disturbance, atopic dermatitis related quality of life, and harms. The network meta-analysis GRADE (Grading of Recommendations Assessment, Development and Evaluation) and Core GRADE approaches informed certainty of evidence ratings. Results: 47 trials enrolled 6230 children and adults with primarily moderate to severe atopic dermatitis. With moderate certainty, compared with placebo, adding a first generation or second generation H1 antihistamine likely resulted in a small reduction in atopic dermatitis severity (mean difference -1.87, 95% credible interval -3.47 to -0.27) and itch severity (-0.89, -1.41 to -0.37). Although statistically detectable, these effects are well below established minimal important differences (smallest change in an outcome that a patient would identify as important). With low certainty, all studied interventions may not improve sleep disturbance or reduce atopic dermatitis exacerbations. First generation agents probably increase cognitive impairment and may increase treatment discontinuation because of adverse events (risk difference 66 more per 1000, 95% credible interval 0 to 231 more; moderate certainty). Second generation agents differ in their risk of cognitive impairment (range of mean effects 0 more per 1000 for loratadine, 16 more per 1000 for levocetirizine, and 17 more per 1000 for cetirizine). Conclusions: Among patients with atopic dermatitis, adding H1 antihistamines probably results in a clinically unimportant reduction in atopic dermatitis severity and itch severity, and may not reduce sleep disturbance or atopic dermatitis exacerbations. First generation agents increase cognitive impairment and may increase treatment discontinuation because of adverse events. Cognitive impairment risk differs among second generation agents. These findings provide evidence against routine antihistamine use in atopic dermatitis management and will inform updated clinical guidelines. Systematic review registration: PROSPERO NCT42022345643 .
- 30 September 2025
- Published by Publicacoes Ciencia e Vida, Lda in Revista Portuguesa de Imunoalergologia
- Vol. 34 (1) , 29-37
Treatment dose increase versus comedication in allergic rhinitis: Systematic review with dose-response network meta-analysis protocol
Background: In patients with allergic rhinitis who remain uncontrolled despite being treated with standard daily doses of a single medication, strategies that can be followed to achieve adequate symptom control include (i) increasing the medication dose, or (ii) adding an additional medication (co-medication). However, it is not known which one of these two strategies is more effective. Objectives: This article describes a protocol of a systematic review with dose-response network meta-analysis aiming at comparing different intranasal and oral medications in patients with seasonal or perennial allergic rhinitis. Methods: We will search four electronic bibliographic databases and three clinical trials databases for randomized controlled trials (i) assessing adults or children with seasonal or perennial allergic rhinitis, and (ii) evaluating the effect of intranasal medications, oral medications or combinations of any intranasal and/or oral medications for allergic rhinitis. Assessed outcomes will include the Total Nasal Symptom Score, the Total Ocular Symptom Score and the Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ). We will assess the methodological quality of included primary studies by using the Cochrane riskof-bias tool. Certainty in the body of evidence for the analysed outcomes will be assessed using the Grading of Recommendations Assessment, Development and Evaluation approach for network meta-analyses (GRADE-NMA). We will perform a frequentist dose-response model-based network meta-analysis. Sensitivity analyses will be performed by separately analysing data for seasonal and perennial allergic rhinitis. Conclusion: This protocol describes the methodology of a systematic review that will fit dose-response network meta-analysis models in the comparison between different intranasal and oral medications. The findings of this systematic review will support recommendations in the Allergic Rhinitis and its Impact on Asthma (ARIA) 2024-2025 guidelines.
- 30 September 2025
- Published by Publicacoes Ciencia e Vida, Lda in Revista Portuguesa de Imunoalergologia
- Vol. 34 (1) , 29-37
Treatment dose increase versus comedication in allergic rhinitis: Systematic review with dose-response network meta-analysis protocol
Background: In patients with allergic rhinitis who remain uncontrolled despite being treated with standard daily doses of a single medication, strategies that can be followed to achieve adequate symptom control include (i) increasing the medication dose, or (ii) adding an additional medication (co-medication). However, it is not known which one of these two strategies is more effective. Objectives: This article describes a protocol of a systematic review with dose-response network meta-analysis aiming at comparing different intranasal and oral medications in patients with seasonal or perennial allergic rhinitis. Methods: We will search four electronic bibliographic databases and three clinical trials databases for randomized controlled trials (i) assessing adults or children with seasonal or perennial allergic rhinitis, and (ii) evaluating the effect of intranasal medications, oral medications or combinations of any intranasal and/or oral medications for allergic rhinitis. Assessed outcomes will include the Total Nasal Symptom Score, the Total Ocular Symptom Score and the Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ). We will assess the methodological quality of included primary studies by using the Cochrane riskof-bias tool. Certainty in the body of evidence for the analysed outcomes will be assessed using the Grading of Recommendations Assessment, Development and Evaluation approach for network meta-analyses (GRADE-NMA). We will perform a frequentist dose-response model-based network meta-analysis. Sensitivity analyses will be performed by separately analysing data for seasonal and perennial allergic rhinitis. Conclusion: This protocol describes the methodology of a systematic review that will fit dose-response network meta-analysis models in the comparison between different intranasal and oral medications. The findings of this systematic review will support recommendations in the Allergic Rhinitis and its Impact on Asthma (ARIA) 2024-2025 guidelines.
- Open Access
- 25 August 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 187, 111944
Use of artificial intelligence to support the assessment of the methodological quality of systematic reviews
- 25 August 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 187, 111944
Open AccessUse of artificial intelligence to support the assessment of the methodological quality of systematic reviews
- Open Access
- 16 July 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 156 (4) , 1008-1023
Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis
- 16 July 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 156 (4) , 1008-1023
Open AccessComparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis
- 7 July 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (7) , 1868-1870
Depemokimab, a Long-Acting (Twice-Yearly) Monoclonal Antibody for Adults and Adolescents With Severe Eosinophilic Asthma
- 7 July 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (7) , 1868-1870
Depemokimab, a Long-Acting (Twice-Yearly) Monoclonal Antibody for Adults and Adolescents With Severe Eosinophilic Asthma
- Open Access
- 29 March 2025
- Published by Wiley in Clinical and Public Health Guidelines
- Vol. 2 (2)
Comparison between two tools assessing the methodological quality of systematic reviews: ReMarQ and AMSTAR 2
Several tools are available for assessing the methodological quality of systematic reviews. The ReMarQ tool – centred on the assessment of the reporting methodological quality of systematic reviews – comprises 26 dichotomous items and does not require clinical or background knowledge of the review topic for its application. In this study, we aimed to compare the results of evaluating the methodological quality of systematic reviews using ReMarQ and A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2. We assessed a sample of randomly selected systematic reviews published in medical journals using ReMarQ and AMSTAR 2. We calculated the correlation and agreement between the number of fulfilled items in ReMarQ and the number of (i) fulfilled and (ii) fulfilled or partially fulfilled items according to AMSTAR 2. We assessed 51 systematic reviews using both tools. The number of fulfilled items in ReMarQ was strongly correlated with the number of fulfilled items ( = 0.79; 95%CI = 0.65;0.87) and the number of fulfilled or partially fulfilled items ( = 0.85; 95%CI = 0.74;0.90) in AMSTAR 2. The percentage of fulfilled ReMarQ items displayed a high agreement with the percentage of fulfilled or partially fulfilled AMSTAR items. In conclusion, the number of fulfilled items in ReMarQ is strongly correlated with that in AMSTAR 2 and there is good agreement between these two tools on the percentage of fulfilled items.
- 29 March 2025
- Published by Wiley in Clinical and Public Health Guidelines
- Vol. 2 (2)
Open AccessComparison between two tools assessing the methodological quality of systematic reviews: ReMarQ and AMSTAR 2
Several tools are available for assessing the methodological quality of systematic reviews. The ReMarQ tool – centred on the assessment of the reporting methodological quality of systematic reviews – comprises 26 dichotomous items and does not require clinical or background knowledge of the review topic for its application. In this study, we aimed to compare the results of evaluating the methodological quality of systematic reviews using ReMarQ and A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2. We assessed a sample of randomly selected systematic reviews published in medical journals using ReMarQ and AMSTAR 2. We calculated the correlation and agreement between the number of fulfilled items in ReMarQ and the number of (i) fulfilled and (ii) fulfilled or partially fulfilled items according to AMSTAR 2. We assessed 51 systematic reviews using both tools. The number of fulfilled items in ReMarQ was strongly correlated with the number of fulfilled items ( = 0.79; 95%CI = 0.65;0.87) and the number of fulfilled or partially fulfilled items ( = 0.85; 95%CI = 0.74;0.90) in AMSTAR 2. The percentage of fulfilled ReMarQ items displayed a high agreement with the percentage of fulfilled or partially fulfilled AMSTAR items. In conclusion, the number of fulfilled items in ReMarQ is strongly correlated with that in AMSTAR 2 and there is good agreement between these two tools on the percentage of fulfilled items.
- Open Access
- 10 September 2024
- Published by Elsevier in World Allergy Organization Journal
- Vol. 17 (9) , 100947
World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update – XI – Milk supplement/replacement formulas for infants and toddlers with CMA – Systematic review
- 10 September 2024
- Published by Elsevier in World Allergy Organization Journal
- Vol. 17 (9) , 100947
Open AccessWorld Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update – XI – Milk supplement/replacement formulas for infants and toddlers with CMA – Systematic review
- Open Access
- 1 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (12) , 2269-2281
Efficacy and safety of COVID-19 vaccination in solid organ transplant recipients: A systematic review and network meta-analysis
- 1 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (12) , 2269-2281
Open AccessEfficacy and safety of COVID-19 vaccination in solid organ transplant recipients: A systematic review and network meta-analysis
- Open Access
- 2 January 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (1) , e0292184
Assessment of reporting quality of randomized controlled trials investigating the effects of inulin-type fructans supplementation on cardiovascular disease risk factors: A systematic survey
Transparent and detailed reporting of randomized controlled trials (RCTs) is essential to judge its validity and generalizability. We assessed the reporting quality of RCTs examining the effects of inulin-type fructans supplementation on cardiovascular risk factors, before and after the publication of the Consolidated Standards of Reporting Trials (CONSORT) in 2010. We searched MEDLINE, EMBASE, Emcare, AMED, the Cochrane Library, and CINAHL from inception to May 15, 2022, including the reference lists of selected RCTs. We screened titles and abstracts and extracted the data independently and in duplicate. We included RCTs that investigated the effects of inulin-type fructans on cardiovascular disease risk factors (e.g., low-density lipoprotein cholesterol, triglycerides, fasting blood glucose) in adults (18 years or older). The primary outcomes of this study were: the overall reporting quality of RCTs (defined as the total number of items [0 to 36] present from the CONSORT checklist) published before and after CONSORT; and the study characteristics (e.g., sample size, significance of primary outcome) predictive of the CONSORT score. The secondary outcome was the reporting of each specific item of the CONSORT checklist during pre- and post-CONSORT periods. The mean difference in the total number of reported items in studies published before and after CONSORT were compared using a t-test and Poisson regression to explore the factors associated with overall reporting quality of RCTs. We used Fisher’s exact test to compare the adherence to each of the 36 items during pre- and post-CONSORT periods. We identified 1,767 citations from our systematic search, of which 55 were eligible. There was a significant increase in the reporting of CONSORT items (mean difference 8.5, 95% confidence interval [CI] 5.24 to 11.71) between studies published before and after publication of CONSORT. The sole variable that was predictive of better reporting quality of RCTs was whether the study was published before or after CONSORT (incidence rate ratio 1.67, 95% CI 1.40 to 2.02). Completeness of reporting of RCTs only improved in 15 out of 36 items (41.6%) after the publication of CONSORT. The completeness of reporting in RCTs investigating inulin-type fructans supplementation on cardiovascular disease risk factors remains inadequate after the publication of CONSORT. Greater adherence to CONSORT by authors and enforcement of CONSORT by journals may improve the quality of reporting among RCTs.
- 2 January 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (1) , e0292184
Open AccessAssessment of reporting quality of randomized controlled trials investigating the effects of inulin-type fructans supplementation on cardiovascular disease risk factors: A systematic survey
Transparent and detailed reporting of randomized controlled trials (RCTs) is essential to judge its validity and generalizability. We assessed the reporting quality of RCTs examining the effects of inulin-type fructans supplementation on cardiovascular risk factors, before and after the publication of the Consolidated Standards of Reporting Trials (CONSORT) in 2010. We searched MEDLINE, EMBASE, Emcare, AMED, the Cochrane Library, and CINAHL from inception to May 15, 2022, including the reference lists of selected RCTs. We screened titles and abstracts and extracted the data independently and in duplicate. We included RCTs that investigated the effects of inulin-type fructans on cardiovascular disease risk factors (e.g., low-density lipoprotein cholesterol, triglycerides, fasting blood glucose) in adults (18 years or older). The primary outcomes of this study were: the overall reporting quality of RCTs (defined as the total number of items [0 to 36] present from the CONSORT checklist) published before and after CONSORT; and the study characteristics (e.g., sample size, significance of primary outcome) predictive of the CONSORT score. The secondary outcome was the reporting of each specific item of the CONSORT checklist during pre- and post-CONSORT periods. The mean difference in the total number of reported items in studies published before and after CONSORT were compared using a t-test and Poisson regression to explore the factors associated with overall reporting quality of RCTs. We used Fisher’s exact test to compare the adherence to each of the 36 items during pre- and post-CONSORT periods. We identified 1,767 citations from our systematic search, of which 55 were eligible. There was a significant increase in the reporting of CONSORT items (mean difference 8.5, 95% confidence interval [CI] 5.24 to 11.71) between studies published before and after publication of CONSORT. The sole variable that was predictive of better reporting quality of RCTs was whether the study was published before or after CONSORT (incidence rate ratio 1.67, 95% CI 1.40 to 2.02). Completeness of reporting of RCTs only improved in 15 out of 36 items (41.6%) after the publication of CONSORT. The completeness of reporting in RCTs investigating inulin-type fructans supplementation on cardiovascular disease risk factors remains inadequate after the publication of CONSORT. Greater adherence to CONSORT by authors and enforcement of CONSORT by journals may improve the quality of reporting among RCTs.